Get started
Author

Shaoshui Chen

Observed names: Shao-Shui Chen, Shao-shui Chen, ShaoShui Chen, Shao‑Shui Chen
ORCID: 0000-0002-7134-9475
Observed ORCID: 0000-0002-7134-9475
OpenAlex ID: A5083446203
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
2022 · Shun Lu, Xiaorong Dong, et al. · Journal of Clinical Oncology · 324
PDF
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
2021 · Shun Lu, Qiming Wang, et al. · Journal of Thoracic Oncology · 153
PDF
Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice
2015 · Fangfang Yang, Jingmin Li, et al. · European Journal of Pharmacology · 99
MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
2014 · Fang-ling Ning, Feng Wang, et al. · Diagnostic Pathology · 78
PDF
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial
2020 · Zhigang Wei, Xia Yang, et al. · European Radiology · 76
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
2024 · Ying Cheng, Wei Zhang, et al. · JAMA Oncology · 75
Thoracic Radiotherapy Improves the Survival in Patients With EGFR -Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial
2024 · Hongfu Sun, Minghao Li, et al. · Journal of Clinical Oncology · 63
Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer
2016 · Zhonghua Zhao, Xi Chen, et al. · Cytokine · 44
Knockdown of c-Myc activates Fas-mediated apoptosis and sensitizes A549 cells to radiation
2017 · Jing Zhang, Ling Zhou, et al. · Oncology Reports · 36
PDF
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
2017 · Jie Xie, Jun Cao, et al. · Breast Cancer Research and Treatment · 33
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
2024 · Shun Lu, Xiaorong Dong, et al. · 癌症：英文版 · 32
PDF
Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).
2021 · Shun Lu, Xiaorong Dong, et al. · Journal of Clinical Oncology · 30
Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
2020 · Shun Lu, Qiming Wang, et al. · Cancer Research · 25
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial
2024 · Jian Zhang, Minghao Li, et al. · 癌症：英文版 · 22
PDF
Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer
2014 · Feng Wang, Fangling Ning, et al. · Cell Biochemistry and Biophysics · 20
Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).
2022 · Shun Lu, Xiaorong Dong, et al. · Journal of Clinical Oncology · 15
Overexpression of miR-939-3p predicts poor prognosis and promotes progression in lung cancer
2019 · Xia Han, Chunjuan Du, et al. · Cancer Biomarkers · 15
PDF
OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
2014 · Yanzhang Hao, Jianwei Liu, et al. · International Journal of Genomics · 14
PDF
Mitigation of acute radiation-induced brain injury in a mouse model using anlotinib
2021 · Xiao-Han Gao, Jing Zheng, et al. · Annals of Palliative Medicine · 13
PDF
Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
2020 · Zhonghan Zhang, Yunpeng Yang, et al. · Annals of Translational Medicine · 12
PDF
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
2022 · Yuankai Shi, Qingyuan Zhang, et al. · Hematological Oncology · 11
Combination of DCE‐MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma
2020 · Changmin Liu, Roger Sun, et al. · BioMed Research International · 10
PDF
Low expression of BEX1 predicts poor prognosis in patients with esophageal squamous cell cancer
2018 · Hai‑Tao Geng, Zhi‑Wen Cheng, et al. · Oncology Reports · 10
PDF
Effects of MiR-210 on proliferation, apoptosis and invasion abilities of esophageal cancer cells.
2018 · Zhiwen Cheng, Haitao Geng, et al. · PubMed · 9
miR-3196 acts as a Tumor Suppressor and Predicts Survival Outcomes in Patients With Gastric Cancer
2020 · Guo Chen, Jinliang Wan, et al. · Technology in Cancer Research & Treatment · 8
Works count: 34
Citation count: 1,246
H-index: 15
I10-index: 23
Year
Topic
Type